Lung Cancer
Advertisement
The study is evaluating if hydrogen peroxide in exhaled breath condensate can be used as a biomarker for lung cancer.
Ravi Rajaram, MD, MSc, discusses Medicaid expansion, timely access to care, regionalization effects, and remaining questions.
Michael R. Gieske, MD, discusses why Lung Cancer Action Week is a key time to promote screening and shares recent milestones.
Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
The ALA and its LUNG FORCE initiative are lighting up buildings and landmarks across the nation this week to inspire action.
Mara Antonoff, MD, discusses key advances and addresses common misconceptions about operating in oligometastatic disease.
The new report from the National Cancer Institute also showed rates of new lung and bronchus cancers fell the most rapidly.
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
Dr. Mara Antonoff discusses why it's critical to offer information and updates on surgery for oligometastatic lung cancer.
John V. Heymach, MD, PhD, of the MD Anderson Cancer Center, presented results from the trial at AACR 2025.
Dr. Le Marchand’s "seminal work has elucidated racial and ethnic disparities in lung cancer risk," officials said.
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
Dr. Ladanyi reflects on genetic hotspot mutations that have not been previously well characterized in lung adenocarcinoma.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
The study authors evaluated the physical, psychosocial, and lifestyle challenges faced by patients with lung cancer.
Most patients with MPM experience pleural effusion, but questions remain about the condition's impact on patient outcomes.
The NCCN 2025 Annual Conference will be held from March 28-30 in Orlando, Florida.
Expanded treatment options for pleural mesothelioma are "urgently needed," due to the high morbidity of the disease.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.